SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Cell therapy
Galapagos to Spin Out Innovative Medicines, Lay Off 40%
By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell therapy company, the latter of which will inherit the Galapagos name.
January 8, 2025
 · 
3 min read
 · 
Tristan Manalac
Photo of a GLP-1 injector pen on a blue background
Weight loss
FDA Proposes Draft Guidance for Weight-Loss Therapies as Obesity Space Heats Up
The FDA recommended maintaining a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of their investigational obesity candidates.
January 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Art collage, hands and falling coins in orange circle. Modern design of finance and business.
IPO
Maze Opens 2025 IPO Class to Advance Kidney Disease Programs
Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in funding to support the development of its kidney disease pipeline.
January 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative pattern made with a syringe on pastel pink background. Vaccine for Coronavirus infection. Pandemic concept.
Vaccines
GSK, Pfizer RSV Shots Required to Carry Guillain-Barré Syndrome Warnings
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments to the vaccines’ labels.
January 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Corporate headquarters of Novo Nordisk in Denmark
Collaboration
Novo Puts $4.6B on the Line to Expand Valo Deal, Maintain Cardiometabolic Leadership
The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with partnerships with Photys Therapeutics, Ascendis Pharma and two Flagship-backed start-ups.
January 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
NextGen Class of 2025, M&A Uptick Predicted Heading Into JPM, FDA Decisions to Watch
BioSpace presents 25 noteworthy biopharma startups in ’25; analysts forecast stronger M&A as the J.P. Morgan Healthcare Conference kicks off next week; GLP-1s continue to expand their reach as Novo, Lilly fight against compounders; and a look ahead to five key FDA decisions in Q1.
January 8, 2025
 · 
1 min read
 · 
Heather McKenzie
Halftone hands reaching for money. Mixed media catch falling coins and cash bills collage, financial success, free wealth and easy money concept vector illustration
Deals
Pharmas Turn to Licensing Deals as Risky Science Rises
Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the biotech ecosystem? Experts weigh in.
January 8, 2025
 · 
3 min read
 · 
Annalee Armstrong
sky with clouds and the glare from the sun
Opinion
A Cautiously Sunny Outlook for Biopharma in 2025
Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, oncology and reaping the benefits of AI.
January 8, 2025
 · 
4 min read
 · 
Bryan Spielman
Group Of Employees Being Fired By Their Company.
Layoffs
CytomX to Cut 40% of Staff as It Updates Pipeline Priorities
CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned clinical-stage programs, most notably an antibody-drug conjugate for advanced metastatic colorectal cancer.
January 7, 2025
 · 
1 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS